Valuation: PREDILIFE

Market Cap 40.25L 46.47L 46.47L 38.06L 34.46L 64.67L 45Cr 65.16L 4.54Cr 1.75Cr 23Cr 1.75Cr 1.71Cr 72Cr P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 88.03L 1.02Cr 1.02Cr 83.24L 75.36L 1.41Cr 97Cr 1.42Cr 9.93Cr 3.82Cr 49Cr 3.82Cr 3.73Cr 157.64Cr EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2004
Chief Tech/Sci/R&D Officer - 01/01/2007
General Counsel - 01/01/2016
Director TitleAgeSince
Chairman 56 01/01/2004
Director/Board Member 46 01/01/2018
Director/Board Member 58 01/01/2018
Change 5-day change 1-year change 3-year change Capi.($)
+1.08%+7.59%+312.33%+77.61% 423.98Cr
+7.67%+9.61%+103.98%+340.26% 425.8Cr
-2.60%-5.44%+25.95%+60.24% 322.69Cr
+0.52%+4.63%+275.46%+564.65% 272.33Cr
-0.98%-2.52%-31.65%-31.64% 207.83Cr
-2.14%-8.44%+38.77% - 157.3Cr
+0.94%+2.54%+23.80%+39.91% 107.84Cr
+2.92%-4.31%+152.94%-34.23% 102.5Cr
+3.15%+2.08%-7.71%+76.62% 62Cr
Average +1.17%-0.10%+99.32%+136.68% 231.36Cr
Weighted average by Cap. +1.48%+1.00%+133.21%+181.80%

Financials

2024 2025
Net sales 5L 6L 6L 5L 4L 8L 5.46Cr 8L 55.65L 21.41L 2.77Cr 21.39L 20.91L 8.83Cr 8L 10L 10L 8L 7L 13.43L 9.26Cr 13.53L 94.32L 36.29L 4.69Cr 36.25L 35.44L 15Cr
Net income -42.65L -49.24L -49.24L -40.33L -36.51L -68.52L -47Cr -69.04L -4.81Cr -1.85Cr -24Cr -1.85Cr -1.81Cr -76Cr -39.34L -45.42L -45.42L -37.2L -33.68L -63.22L -44Cr -63.69L -4.44Cr -1.71Cr -22Cr -1.71Cr -1.67Cr -70Cr
Net Debt 35.38L 40.85L 40.85L 33.46L 30.29L 56.85L 39Cr 57.28L 3.99Cr 1.54Cr 20Cr 1.53Cr 1.5Cr 63Cr 47.78L 55.16L 55.16L 45.18L 40.9L 76.76L 53Cr 77.34L 5.39Cr 2.07Cr 27Cr 2.07Cr 2.03Cr 86Cr
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!